Economic Impact of Including Sequential Bevacizumab for the Treatment of Patients with Kirsten Ras Wild Type Unresectable Metastatic Colorectal Cancer in Four Latin American Countries

Abstract

the respective countries were elicited from local experts and clinical guidelines in addition to 1L> 2L BEV sequences obtained from the ML18147 trial. Results: When 1L> 2L BEV replaces sequences which include 1L anti-EGFR regimens, it results in an average potential cost reduction of 796